Beating the Odds in Healthcare: How Private Equity Firms Can Improve Exit Prospects in a Sector That Refuses to Slow Down

March 2026 | Healthcare Venture Capital Fund Research

Healthcare private equity reached a record $191 billion in disclosed deal value in 2025, surpassing the previous 2021 peak. Exit value rebounded to an estimated $156 billion, nearly triple the $54 billion posted in 2024. Yet a backlog of more than 16,000 portfolio companies globally, many held beyond four years, signals that the ability to prepare and execute successful exits remains the defining factor separating top-performing healthcare PE funds from everyone else.

This analysis adapts and extends the exit preparation framework originally published by McKinsey & Company, layering in healthcare-specific data, regulatory dynamics, and sector intelligence to help healthcare PE sponsors, family offices, and institutional investors navigate one of the most consequential exit environments in a generation.

The Healthcare Exit Landscape: A Sector Apart

Private equity exits across all sectors faced headwinds over the past several years: elevated financing costs, volatile equity markets, rigorous buyer scrutiny, and uncertainty around input costs amplified by US tariff policy. Healthcare was not immune to these forces, but it responded differently than most sectors.

Healthcare PE disclosed deal value exceeded an estimated $191 billion in 2025, marking the highest annual total on record. Deal activity was similarly robust: investors announced an estimated 445 buyouts, the second highest annual total behind 2021. More than 40 deals cleared the $1 billion threshold in 2025, compared with only 16 in 2024.

Exits also surged. Healthcare exit value reached approximately $156 billion in 2025, a dramatic recovery from the $54 billion recorded the prior year. Sponsor-to-sponsor deals rebounded from post-pandemic lows, strategic acquisitions remained active, and selective IPO windows opened for well-positioned assets.

Yet the backlog persists. Across all PE sectors, an estimated 16,000 companies ready to exit but held for more than four years sit on sponsor balance sheets. That figure represents 52 percent of total buyout-backed inventory as of 2025, the highest proportion on record and ten percentage points above the five-year average. The average global holding period has reached a historic high of 6.6 years.

For healthcare sponsors specifically, this creates a paradox. The sector’s fundamentals are as strong as any in private equity: nondiscretionary demand, insurance-funded revenue, demographic tailwinds from 72 million Americans approaching age 65 by 2030, and a regulatory environment increasingly favorable to outpatient delivery and technology adoption. But strong fundamentals alone do not produce timely exits. That requires disciplined preparation, healthcare-specific positioning, and the flexibility to adapt exit strategies to a market where buyer expectations, reimbursement dynamics, and clinical validation requirements add layers of complexity that generalist PE frameworks rarely address.

Seven Strategies for Successful Healthcare Exits

1. Embed Exit Planning Into the Healthcare Acquisition Thesis

Leading healthcare PE firms begin thinking about exits at the moment of acquisition, linking the investment thesis and target holding period to the planned exit strategy. In healthcare, this means the acquisition diligence itself must evaluate exit-specific variables that do not exist in other sectors: reimbursement concentration risk, payer mix stability, regulatory approval timelines, clinical workforce retention, and the physical infrastructure requirements of the care delivery model.

A physician practice management platform acquired with a three-year hold thesis, for example, requires a fundamentally different exit preparation cadence than a healthcare IT company targeting a five-to-seven-year hold. The practice management asset faces physician employment agreement expirations, non-compete enforceability questions, and Medicare reimbursement rate resets that must be sequenced against the exit timeline. The healthcare IT company faces product roadmap milestones, FDA clearance timelines, and enterprise contract renewals that determine revenue visibility at exit.

Many healthcare PE firms now revisit their initial exit plan every six to twelve months, testing alignment with the asset’s growth trajectory and shifting market conditions. They formalize exit-readiness plans 12 to 18 months ahead of a planned divestment to identify areas where they can create additional value and address roadblocks before they become deal-killers.

2. Establish Rigorous Exit Governance With Healthcare-Specific Benchmarks

Firms succeeding in the current healthcare exit environment plan exits at the portfolio level, aligning individual transactions with fund-level liquidity goals. They treat exits not as isolated events but as part of an integrated capital rotation plan.

In healthcare, this governance model must account for sector-specific timing constraints. A behavioral health platform cannot be marketed for sale during a state licensure renewal cycle. A specialty pharmacy roll-up faces different buyer scrutiny windows depending on PBM contract timing. An ambulatory surgery center network must demonstrate consistent same-store procedure volume growth across at least four quarters before buyer diligence teams will credit the growth as sustainable.

Top-performing healthcare sponsors establish dedicated exit committees that include senior fund leadership, deal partners, and operating team members with clinical or healthcare operations backgrounds. Portfolio company management teams report regularly on operational maturity, regulatory compliance status, and clinical quality metrics. Every quarter, the committee evaluates an exit-readiness scorecard for each portfolio company, factoring in healthcare-specific dimensions: payer contract renewal schedules, physician retention rates, patient satisfaction scores, quality measure performance, and pending regulatory actions.

3. Map the Universe of Healthcare Buyers Early and Continuously

Healthcare buyer mapping requires a fundamentally different approach than mapping buyers in industrials or technology. The healthcare acquirer universe includes at least five distinct buyer categories, each with different motivations, diligence requirements, and valuation frameworks:

• Strategic corporate buyers (health systems, large physician groups, payers) who evaluate acquisitions through the lens of network expansion, value-based care positioning, and clinical integration.
• Financial sponsors (other PE firms) seeking platform assets or add-on acquisitions for existing healthcare portfolio companies.
• Large pharmaceutical and medtech companies acquiring AI-enabled assets, clinical data platforms, or distribution capabilities.
• International acquirers, though US tariff policy and geopolitical uncertainty have cooled interest from some foreign buyers who were initially identified as likely acquirers.
• IPO markets, which have been muted for healthcare since 2021 but showed selective openings in 2025 for well-positioned assets.

Systematic buyer mapping in healthcare must also account for regulatory constraints on ownership. Several states restrict or prohibit corporate practice of medicine, which limits the buyer universe for physician-led platforms. Certificate-of-need requirements in certain states create barriers to facility-based acquisitions. And payer contracting requirements mean that a change of control can trigger renegotiation of reimbursement rates, a risk that must be disclosed and managed during the exit process.

Leading sponsors increasingly plan for multiple exit paths rather than relying on a single buyer universe. When pricing gaps or regulatory uncertainty delay a sale, they develop credible alternatives: pursuing additional acquisitions to build scale, repositioning the asset for an IPO, structuring a continuation vehicle, or extending the holding period with renewed value creation.

4. Build Value-Creation Plans Around Healthcare-Specific Growth Levers

Growth and profitability remain the strongest determinants of exit success across all PE sectors. Across Europe over the past six years, assets growing at more than 25 percent compound annual growth rate have sold at roughly a 50 percent premium relative to assets growing below 5 percent, and higher EBITDA margins also correlate with stronger valuations.

In healthcare, value-creation plans must address growth levers that are unique to the sector. Revenue growth in healthcare is driven by volume (patient encounters, procedures, prescriptions), rate (reimbursement per encounter), and mix (shifting toward higher-acuity, higher-margin services). Each lever carries different risk profiles and different credibility with buyers.

Volume growth from organic patient acquisition is the most durable and the most valued by acquirers. Rate growth from payer contract renegotiation is credible but time-bound. Mix shift toward higher-margin services (such as adding ambulatory surgery capabilities to a specialty practice or launching a cash-pay longevity medicine vertical) can demonstrate strategic vision, but requires clinical validation that the new service line is sustainable.

Around 54 percent of overall revenue growth from PE deals is generated through value-creation initiatives, 32 percent through multiple expansions, and the remaining 14 percent from margin improvement. In healthcare, the most compelling value-creation stories combine operational efficiency gains (revenue cycle optimization, clinical workflow automation, supply chain consolidation) with demonstrated clinical outcomes improvement, because buyers increasingly evaluate whether operational gains came at the expense of patient care or in service of it.

Some healthcare PE firms deliberately leave a few value-creation opportunities untapped before exit. During vendor due diligence, they showcase that they completed the first phase of a cost-efficiency program while mapping out the second phase to demonstrate a credible runway for the next buyer.

5. Launch Value-Capture Sprints in the Final 12 to 18 Months

Around 12 to 18 months before a planned divestment, healthcare PE firms can accelerate initiatives that demonstrate growth momentum and reinforce the exit story. These value-capture sprints focus on levers that deliver visible impact quickly: pricing optimization, revenue cycle management improvements, denials reduction, clinical staffing efficiency, and digital patient acquisition.

In healthcare, growth initiatives typically need to be launched at least two years prior to exit for their impact to materialize by divestment time. Cost-saving measures can be launched later in the cycle. The most effective healthcare-specific value-capture sprints combine operational improvements with clinical quality metrics, demonstrating to buyers that the business is getting both more efficient and better at delivering care.

Primary value creation, typically achieved in the first 18 to 24 months through structural performance improvements, can lift an asset’s total equity value by 20 to 50 percent. Value-capture sprints executed closer to exit time can add an additional 10 to 25 percent to equity value. In healthcare, examples include implementing AI-driven clinical documentation that reduces physician administrative burden and increases billable encounters, launching a digital scheduling platform that reduces patient no-show rates, or introducing predictive analytics for chronic disease management that improves quality scores and positions the asset favorably for value-based contracts.

6. Demonstrate AI Readiness as a Core Exit Asset

During diligence, healthcare buyers are increasingly assessing AI readiness across clinical operations, revenue cycle, patient engagement, and administrative functions. This assessment has moved from a nice-to-have to a deal-shaping factor. Portfolio companies that can demonstrate a clear AI strategy, deployed use cases, and measurable impact command premium valuations. Those that cannot face discount pressure.

Healthcare IT returns have outpaced other healthcare subsectors since 2017, and healthcare IT now accounts for nearly 20 percent of healthcare PE transactions, up from 15 percent in 2021. AI is the primary driver of this shift. More healthcare venture capital investment went to deals exceeding $300 million with AI components in 2025 than in any other year measured. AI now represents 46 percent of all healthcare investment.

Successful healthcare sponsors take a structured approach to AI readiness across three dimensions:

• Strategy: Define a clear AI roadmap with quantified cost and revenue impact across priority use cases. In healthcare, this means mapping AI applications to specific clinical and administrative workflows: ambient documentation, clinical decision support, revenue cycle automation, patient scheduling optimization, and predictive analytics for population health.
• Talent and operating model: Establish a scalable AI operating model with clear roles and targeted hiring. Healthcare presents unique talent challenges because AI deployment in clinical settings requires professionals who understand both the technology and the regulatory requirements of clinical workflows, HIPAA compliance, and FDA oversight of AI-enabled medical devices.
• Technology, data, and execution: Implement priority use cases ahead of exit to demonstrate readiness. In healthcare, this means showing buyers that AI tools are not experiments but deployed systems generating measurable ROI: reduced claim denials, shorter revenue cycle times, improved clinical documentation accuracy, or lower patient acquisition costs.

7. Address Healthcare-Specific Exit Risks That Kill Deals

Healthcare exits fail for reasons that rarely surface in other sectors. The most common deal-killers include:

• Reimbursement concentration: Over-reliance on a single payer or government program creates binary risk that sophisticated buyers will discount heavily. Assets with diversified payer mixes and demonstrated ability to renegotiate commercial rates command materially higher multiples.
• Physician dependency: Platform companies where revenue concentrates in a small number of physician producers face key-person risk that buyers struggle to underwrite. Successful exit preparation requires demonstrating that the platform, not individual physicians, drives patient volume and clinical outcomes.
• Regulatory and compliance exposure: Pending state licensure issues, Medicare audit findings, or Stark Law and Anti-Kickback Statute compliance questions will stall or kill a healthcare exit faster than any financial metric. Pre-exit compliance audits are essential.
• Clinical quality gaps: As healthcare PE comes under increasing public and political scrutiny, buyers are conducting deeper clinical quality diligence. Patient outcome data, safety event reporting, staffing ratios, and quality measure performance are becoming standard diligence items, not afterthoughts.
• Real estate and infrastructure gaps: Healthcare businesses require physical infrastructure to scale. Ambulatory surgery centers, specialty clinics, and diagnostic facilities involve long-term leases, specialized buildouts, and certificate-of-need requirements. Buyers evaluate whether the real estate strategy supports or constrains the growth thesis.

Where the Capital Is Flowing: Healthcare Subsectors Driving Exits

Not all healthcare subsectors are created equal for exit purposes. The current market shows clear patterns in where buyer appetite is strongest and where premiums are being paid.

Provider and Physician Platforms

Strategic acquirers and well-capitalized sponsors are targeting physician specialties including oncology, gastroenterology, urology, dental services, and behavioral health. Investors are retooling their physician group approach, building performance-driven platforms for the long term and positioning assets for strategic exits. The emphasis has shifted from rapid aggregation to demonstrating clinical quality, operational maturity, and sustainable unit economics.

Healthcare IT and AI-Enabled Assets

Healthcare IT has shown outsized growth since 2020 and now commands a disproportionate share of transaction activity. Buyers are particularly focused on revenue cycle management automation, ambient clinical documentation, interoperability platforms, and predictive analytics. AI-native companies with deployed products and measurable clinical impact are attracting the highest multiples. The convergence of AI and healthcare IT is creating a new class of exit-ready assets that did not exist five years ago.

Home Health, Behavioral Health, and Post-Acute Care

Accelerating consolidation continues in post-acute care sectors. Home health, hospice, and behavioral health platforms with established clinical protocols, strong outcomes data, and diversified payer mixes remain highly attractive. PE sponsors favor these assets for their recession-resistant characteristics: predictable Medicaid and Medicare-funded revenue streams, sticky patient populations, and growing demographic demand.

Medtech and Digital Health Devices

Medtech has shown outsized growth since 2020, with particular interest in remote monitoring, care coordination, and patient engagement technologies. More than 1,000 AI-enabled medical devices now carry FDA clearance, and the pace of approvals continues to accelerate. For PE sponsors holding medtech assets, FDA clearance status, clinical evidence quality, and reimbursement pathway clarity are the primary determinants of exit valuation.

Longevity and Healthspan Technology

Longevity and healthspan technology saw a massive increase in healthcare investment in 2025. While the surge was concentrated in a small number of large deals, the underlying trend reflects growing institutional conviction in the science of extending human healthspan. This subsector remains early-stage for large-scale PE exits, but the companies building diagnostic platforms for early disease detection, wearable biosensors, and AI-powered health optimization are positioning themselves as future exit candidates as the market matures.

Continuation Vehicles: A Healthcare-Specific Consideration

Continuation vehicles have become a preferred mechanism for healthcare PE sponsors seeking to retain exposure to resilient, cash-generative businesses beyond the natural life of their funds. In healthcare, they have gained particular traction in contract research organizations, contract development and manufacturing organizations, and healthcare services, sectors with strong growth but limited near-term exit options.

These transactions provide flexibility when market conditions or pricing do not support a full exit. However, they carry risks: valuation scrutiny from LPs, potential alignment challenges between continuing and exiting investors, and the need for a credible value-creation plan that justifies the reset ownership structure. In healthcare, the value-creation plan must address the sector-specific question of whether the extended hold period will generate additional clinical evidence, payer contract improvements, or operational scale that would not be achievable under the original fund timeline.

The Infrastructure Bridge: Where Buildings Meet Exits

Every healthcare exit involves a real estate dimension that most sponsors underestimate. The ambulatory surgery center network being marketed to a strategic buyer requires a real estate portfolio evaluation alongside the clinical and financial diligence. The behavioral health platform scaling into new states needs lease negotiations, buildout timelines, and certificate-of-need filings that directly impact the buyer’s underwriting of future growth.

Healthcare real estate is not a separate investment category. It is the physical infrastructure that determines whether a healthcare operating company can execute its growth plan. Vacancy rates in medical office buildings sit below ten percent nationally. Healthcare tenants rarely relocate after investing hundreds of dollars per square foot in specialized buildouts. And rent collections held above 95 percent through both the 2008 financial crisis and the COVID-19 pandemic.

For healthcare PE sponsors preparing an exit, the real estate strategy can either accelerate or constrain the transaction. Assets with favorable lease terms, owned real estate that can be separated into a sale-leaseback, or expansion-ready sites in high-growth markets present differently to buyers than assets locked into unfavorable leases, aging facilities, or markets where suitable real estate is scarce.

Healthcare Venture Capital Fund and its affiliate Healthcare Real Estate Fund operate on both sides of this equation. We evaluate healthcare venture opportunities with the operational fluency of real estate principals who understand buildout costs, tenant retention dynamics, and market supply constraints. For sponsors seeking a real estate partner to support portfolio company expansion without diluting equity, we offer a bridge between the operating company and the physical infrastructure it needs to scale.

The Path Forward

A successful healthcare PE exit in 2026 and beyond requires more than favorable market timing. It requires a disciplined, healthcare-specific approach to exit preparation that accounts for the sector’s unique regulatory environment, reimbursement dynamics, clinical quality imperatives, and infrastructure requirements.

The sponsors that will outperform are those that embed exit planning from acquisition, build governance frameworks that account for healthcare’s complexity, map buyer universes that reflect the sector’s distinct acquirer categories, and demonstrate AI readiness as a core asset rather than an afterthought.

Healthcare private equity posted a record year in 2025. The backlog of mature assets, the abundance of dry powder, and the structural tailwinds of demographic demand all point to continued momentum. But momentum alone does not produce returns. Execution does. And in healthcare, execution means understanding that every clinical workflow, every regulatory approval, every payer contract, and every physical facility contributes to the exit story that ultimately determines whether a sponsor captures the full value of what it built.

About Healthcare Venture Capital Fund

Healthcare Venture Capital Fund invests in the companies, platforms, and breakthrough technologies reshaping how healthcare is discovered, delivered, and scaled. Our founding team brings operational experience from healthcare real estate, clinical operations, and capital markets to evaluate venture opportunities with a level of sector fluency that purely financial sponsors rarely possess.

For healthcare intelligence and research: HealthcareDiscovery.ai

For healthcare real estate investment: HealthcareRealEstateFund.com

Contact: partners@healthcareventurecapitalfund.com

Sources include Bain & Company Global Healthcare Private Equity Report 2026, Cherry Bekaert Private Equity Report 2026, PwC 2026 Healthcare Investment Themes, Silicon Valley Bank Healthcare Investments and Exits Report H1 2026, DLA Piper Healthcare M&A Outlook 2026, and McKinsey & Company.